Nektar Therapeutics (NKTR) Misses Q1 EPS by 69c, Miss on Revenues
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $66.84 -0.39%
EPS Growth %: -215.1%
Financial Fact:
Cost of goods sold: 7.03M
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: -215.1%
Financial Fact:
Cost of goods sold: 7.03M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.60), $0.69 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $38.02 million versus the consensus estimate of $140.61 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)
- Microchip Technology completes acquisition of Hailo
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
